Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients

Summary

This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis. Subjects that have negative CMV CMI will receive antiviral prophylaxis for 2 months and those with positive CMV CMI will have their prophylaxis stopped.

Timeline

Start

2014-11

Primary completion

2016-09

Completion

2017-06-16

Drugs

Indications